Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

Walchner, Monika; Meurer, Michael; Plewig, Gerd; Messer, Gerald

doi:10.1046/j.1365-4362.2000.00866.x

Cited by 63 publications

(34 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The angiogenic process, its mediators and inhibitors, cellular and molecular interactions underlying neovascularization, as well as the role of angiogenesis and the possibilities of angiostatic targeting in RA are extensively discussed in a number of reviews [1][2][3][4][5][6][7][8][9]. In contrast, less information is available on the role of neovascularization in other systemic inflammatory (autoimmune) conditions, such as systemic sclerosis (scleroderma, SSc), systemic lupus erythematosus (SLE), polymyositis/ dermatomyositis (PM/DM), Sjögren's syndrome (SS), mixed connective tissue disease (MCTD) or systemic vasculitides [10][11][12][13][14][15][16][17][18]. Therefore, the most important angiogenic mediators and inhibitors, and their role in neovascularization will be discussed in context with RA.…”

Section: Angiogenesis In Rheumatoid Arthritismentioning

confidence: 99%

See 1 more Smart Citation

Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases

Bodolay

Koch

Kim

et al. 2002

J Cellular Molecular Medi

100

View full text Add to dashboard Cite

Angiogenesis, the formation of new vessels, is important in the pathogenesis of rheumatoid arthritis (RA) and other inflammatory diseases. Chemotactic cytokines termed chemokines mediate the ingress of leukocytes, including neutrophils and monocytes into the inflamed synovium. In this review, authors discuss the role of the most important angiogenic factors and angiogenesis inhibitors, as well as relevant chemokines and chemokine receptors involved in chronic inflammatory rheumatic diseases. RA was chosen as a prototype to discuss these issues, as the majority of studies on the role of angiogenesis and chemokines in inflammatory diseases were carried out in arthritis. However, other systemic inflammatory (autoimmune) diseases including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS), mixed connective tissue disease (MCTD), polymyositis/dermatomyositis (PM/DM) and systemic vasculites are also discussed in this context. As a number of chemokines may also play a role in neovascularizaton, this issue is also described here. Apart from discussing the pathogenic role of angiogenesis and chemokines, authors also review the regulation of angiogenesis and chemokine production by other inflammatory meditors, as well as the important relevance of neovascularization and chemokines for antirheumatic intervention.

show abstract

Section: Angiogenesis In Rheumatoid Arthritismentioning

confidence: 99%

“…In SLE, thalidomide, a potent angiogenesis inhibitor with other antiinflammatory effects had some effect on clinical and laboratory markers of disease activity [10].…”

Section: Angiogenesis In Systemic Autoimmune Diseasesmentioning

confidence: 99%

Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases

Bodolay

Koch

Kim

et al. 2002

J Cellular Molecular Medi

100

View full text Add to dashboard Cite

show abstract

“…In particular, some clinical trials support the efficacy of thalidomide for cutaneous manifestation of SLE [45]. However, due to its neurotoxicity, the drug is indicated in patients who do not respond to standard therapeutic regimens [46].…”

Section: Drugs Depleting B Cellsmentioning

confidence: 99%

New perspectives in treatment of glomerulonephritis

Coppo

Amore

2004

Pediatric Nephrology

View full text Add to dashboard Cite

In chronic glomerulonephritis (GN) the development of the tissue damage and progression to fibrosis is related to the individual immune response which brings about excessive inflammation, failure to activate regression and glomerular repair and excessive fibrogenic activity. Therefore, the present standard treatment of GN has two aims, to fight the acute inflammation and to inhibit the progressive renal fibrosis. New avenues in the anti-inflammatory and immunosuppressive treatment of the active phase of glomerular diseases include the use of drugs proven to be of value in organ transplantation (mycophenolate mofetil, rapamycin or anti-immune adhesion and anti-co-stimulatory molecules). Interest has recently focused on anti-inflammatory cytokines (monoclonal antibodies, peptidic antagonists or anti-sense oligonucleotides against TNF-alpha, anti-PDGF-beta, anti-TGF-beta and cytokine receptor antagonists) and anti-inflammatory natural cytokines (such as IL4, IL10, IL13 or low doses of TGFbeta). Other drugs may act by depleting B cells (such as anti-CD20 monoclonal antibody) or on several immune pathways, such as thalidomide or anti-cyclooxygenase 2. Several anti-sclerogenic drugs are already used for treatment of the chronic phase of glomerular diseases, such as antagonists of angiotensin II, statins and antioxidants. Other drugs are still experimental, including endothelin receptor antagonists and neutral endopeptidase or vasopeptidase inhibitors and other drugs operating on extracellular matrix accumulation/degradation mechanisms, e.g., pirfenidone. There are extremely interesting developments concerning activators of endogenous anti-inflammatory mechanisms, such as those regulated by peroxisome proliferator activated receptors. There is a need for successful treatment of chronic GN in childhood. This short review of the most promising new drugs shows there is reason to believe that the next decade will provide exciting new tools for the treatment of these diseases in children.

show abstract

“…9 This drug has since been reintroduced selectively for the treatment of diseases with an underlying autoimmune or inflammatory mechanism. 10 Thalidomide has been found useful for the treatment of diseases such as erythema nodosum leprosum, 11,12 sarcoidosis, 13 prurigo nodularis, 14 discoid lupus erythematosus, 15,16 aphthous manifestations including Behçet syndrome, 17,18 pyoderma gangrenosum, 19 rheumatoid arthritis, and graftvs-host disease. 20,21 These observations and the postulated inhibitory action of thalidomide on TNF-␣ production prompted us to consider thalidomide therapy in our patient as well.…”

Section: Commentmentioning

confidence: 99%